Biotech business Pneumagen has appointed James Noble as non-executive chair of its board.
He brings more than 30 years of industry experience, from both public and private biotech and healthcare companies.
Noble is currently also chair at Orexo, Sutura Therapeutics and Celleron Therapeutics, and non-executive director of Lava Therapeutics.
He has previously held non-executive roles at MediGene, PowderJect, Oxford GlycoSciences, CuraGen, Advanced Medical Solutions and GW Pharmaceuticals.
In 2008, Noble founded Adaptimmune, a T-cell therapy company, where he worked as chief executive until 2019 - and is currently on the board. Prior to that, he served as chief executive of Immunocore, which he also co-founded.
Douglas Thomson, chief executive of Pneumagen, commented: “James’ considerable experience will be invaluable as we progress our Phase 2 clinical trial with our lead asset, Neumifil.
“We look forward to leveraging James’ global network and deep knowledge of the biotech sector as we continue our commitment to deliver an important new therapy to vulnerable patients at risk from viral RTIs.”
The St Andrews-based business is developing Neumifil, a broad-spectrum antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (RTIs).
Noble added: “I look forward to working closely with the company’s impressive team and driving forward the strategy to deliver such a potentially important new product for patients at high-risk of viral-induced exacerbations caused by respiratory viruses.”
Pneumagen was established in 2016 as a spin-out from the University of St Andrews.
Don't miss the latest headlines with our twice-daily newsletter - sign up here for free.
